ESMO 2021: First-line nivolumab/ipilimumab – probability of survival in 5-year follow-up
The use of two medicines together (combination therapies) for previously [...]
ESMO 2021: Alternative treatment schedule for ipilimumab plus nivolumab in first-line treatment of advanced RCC (PRISM)
Ipilimumab plus nivolumab is a standard first-line treatment for patients [...]
ASCO 2021: Nivolumab plus ipilimumab for the treatment of kidney cancer brain metastases
Brain metastases resulting from the spread of renal cell carcinoma [...]
ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination
Long-term follow-up data from the CheckMate-214 study of the nivolumab [...]
ASCO GU 2021: Nivolumab plus ipilimumab combination in patients with non-clear cell kidney cancer
Data from the CheckMate-920 study on the safety and effectiveness [...]
Pembrolizumab as first-line treatment for kidney cancer
The recent phase II KEYNOTE-427 study investigated the efficacy and [...]
Nivolumab plus ipilimumab for first-line treatment of advanced kidney cancer: Extended 4-year follow-up
Four-year follow up data are now available from the CheckMate [...]
Survival outcomes for patients on ipilimumab plus nivolumab combination therapy
Further results from the ongoing CheckMate 214 phase III study [...]
ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer
Results from the phase II FRACTION-RCC clinical trial to assess [...]
ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab
Two studies were presented during the 2020 American Society of [...]
